Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX.
Division of Endocrinology, Department of Medicine, University of Texas Health Science Center, San Antonio, TX.
Diabetes. 2024 Feb 1;73(2):197-210. doi: 10.2337/db23-0571.
Partial leptin reduction can induce significant weight loss, while weight loss contributes to partial leptin reduction. The cause-and-effect relationship between leptin reduction and weight loss remains to be further elucidated. Here, we show that FGF21 and the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide rapidly induced a reduction in leptin. This leptin reduction contributed to the beneficial effects of GLP-1R agonism in metabolic health, as transgenically maintaining leptin levels during treatment partially curtailed the beneficial effects seen with these agonists. Moreover, a higher degree of leptin reduction during treatment, induced by including a leptin neutralizing antibody with either FGF21 or liraglutide, synergistically induced greater weight loss and better glucose tolerance in diet-induced obese mice. Furthermore, upon cessation of either liraglutide or FGF21 treatment, the expected immediate weight regain was observed, associated with a rapid increase in circulating leptin levels. Prevention of this leptin surge with leptin neutralizing antibodies slowed down weight gain and preserved better glucose tolerance. Mechanistically, a significant reduction in leptin induced a higher degree of leptin sensitivity in hypothalamic neurons. Our observations support a model that postulates that a reduction of leptin levels is a necessary prerequisite for substantial weight loss, and partial leptin reduction is a viable strategy to treat obesity and its associated insulin resistance.
部分瘦素减少可引起显著的体重减轻,而体重减轻有助于部分瘦素减少。瘦素减少和体重减轻之间的因果关系仍有待进一步阐明。在这里,我们表明,成纤维细胞生长因子 21(FGF21)和胰高血糖素样肽 1 受体(GLP-1R)激动剂利拉鲁肽可迅速引起瘦素减少。这种瘦素减少有助于 GLP-1R 激动剂在代谢健康方面的有益作用,因为在治疗过程中转基因维持瘦素水平部分削弱了这些激动剂的有益作用。此外,用 FGF21 或利拉鲁肽结合瘦素中和抗体治疗时,可更显著地降低瘦素水平,从而在饮食诱导的肥胖小鼠中协同诱导更大的体重减轻和更好的葡萄糖耐量。此外,在停止使用利拉鲁肽或 FGF21 治疗后,观察到预期的即时体重反弹,同时循环瘦素水平迅速升高。用瘦素中和抗体预防这种瘦素激增可减缓体重增加并保持更好的葡萄糖耐量。从机制上讲,瘦素的显著减少导致下丘脑神经元的瘦素敏感性更高。我们的观察结果支持这样一种模型,即瘦素水平的降低是实质性体重减轻的必要前提,部分瘦素减少是治疗肥胖及其相关胰岛素抵抗的可行策略。